Insights from 2024 WCLC


 

WCLC 2024 Insights: Highlights of Coming Advances in mNSCLC - Cytotoxics, IO, and KRAS Inhibitors

114 views
September 19, 2024

Chapters

Overview & Speaker Introduction

00:00

Dato-DXd vs. Docetaxel: Phase III Results

00:32

TROP2 Biomarker & Dato-DXd Efficacy

03:48

Volrustomig & Chemotherapy in mNSCLC

05:59

KRAS G12C Inhibitors: Divarasib Update

10:18

Key Takeaways & Future Considerations

14:18

0 Comments
Login to view comments. Click here to Login